{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:10:30Z","timestamp":1783645830103,"version":"3.55.0"},"reference-count":47,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,1,12]],"date-time":"2012-01-12T00:00:00Z","timestamp":1326326400000},"content-version":"vor","delay-in-days":407,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:p>Relief of benign prostatic hyperplasia (BPH)\u2010related lower urinary tract symptoms by \u03b1\u2010blockers (\u03b1\u2010adrenoceptor antagonists) is mediated primarily through the blockade of \u03b1<jats:sub>1A<\/jats:sub>\u2010receptors, leading to relaxation of smooth muscle in the prostate and bladder neck. Early \u03b1\u2010blockers that were nonselective for adrenoceptor subtypes have been associated with blood pressure\u2010related adverse effects, such as orthostatic hypotension, that may be attributed at least in part to the blockade of \u03b1<jats:sub>1B<\/jats:sub>\u2010adrenoceptors in arterial vessels. Silodosin, a novel \u03b1\u2010blocker with exceptionally high selectivity for \u03b1<jats:sub>1A<\/jats:sub>\u2010 versus \u03b1<jats:sub>1B<\/jats:sub>\u2010adrenoceptors, was recently approved in the United States for the treatment of urinary symptoms related to BPH. The unique receptor selectivity profile likely accounts for some of the desirable clinical features of the drug. Silodosin possesses an excellent cardiac\u2010 and blood pressure\u2010related safety profile, and data have demonstrated that it does not promote QT\u2010interval prolongation. Therapeutic doses of silodosin are safe for men with mild\u2010to\u2010moderate liver dysfunction; dosage adjustment is recommended in those with moderate renal impairment. The drug should not be taken with potent cytochrome P450 3A4 inhibitors. Silodosin may be especially beneficial in patients who need to maximize cardiovascular tolerability.<\/jats:p>","DOI":"10.1592\/phco.30.12.1303","type":"journal-article","created":{"date-parts":[[2010,11,29]],"date-time":"2010-11-29T12:02:27Z","timestamp":1291032147000},"page":"1303-1312","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Silodosin for the Treatment of Benign Prostatic Hyperplasia: Pharmacology and Cardiovascular Tolerability"],"prefix":"10.1002","volume":"30","author":[{"given":"Herbert","family":"Lepor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,12]]},"reference":[{"key":"e_1_2_1_2_2","volume-title":"Urologic diseases in America","author":"Wei JT","year":"2009"},{"issue":"7","key":"e_1_2_1_3_2","first-page":"S3","article-title":"Pathophysiology of lower urinary tract symptoms in the aging male population","volume":"7","author":"Lepor H.","year":"2005","journal-title":"Rev Urol"},{"key":"e_1_2_1_4_2","first-page":"181","article-title":"\u03b1\u2010Blockers for the treatment of benign prostatic hyperplasia","volume":"9","author":"Lepor H.","year":"2007","journal-title":"Rev Urol"},{"key":"e_1_2_1_5_2","unstructured":"American Urological Association (AUA).Chapter 1. AUA guideline on the management of benign prostatic hyperplasia: diagnosis and treatment recommendations 2003 (updated 2006). Available fromhttp:www.auanet.orgcontentguidelines\u2010and\u2010quality\u2010careclinical\u2010guidelines.cfmsubbph. AccessedNovember 24 2009."},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2007.01956.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)66704-1"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0026-895X(25)10156-9","article-title":"The \u03b11\u2010adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human \u03b11c subtype","volume":"45","author":"Forray C.","year":"1994","journal-title":"Mol Pharmacol"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.08.080"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.360"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707679"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpuro0836"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000067621.62736.7c"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1994.tb17053.x"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.23.2336"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0026-895X(25)10243-5","article-title":"KMD\u20103213, a novel, potent, \u03b11A\u2010adrenoceptor\u2010selective antagonist: characterization using recombinant human \u03b1\u2010adrenoceptors and native tissue","volume":"48","author":"Shibata K.","year":"1995","journal-title":"Mol Pharmacol"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.02.034"},{"key":"e_1_2_1_18_2","unstructured":"GittelmanMC HillL. VolinnW.HoelG.Efficacy and safety of silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH): pooled results of 2 multicenter randomized double\u2010blind placebo\u2010controlled parallel\u2010group phase 3 studies [abstract].Presented at the New England section American Urological Association 77th annual meeting Rio Grande Puerto Rico September 25\u201327 2008. Available fromhttp:www.neaua.org2008Abstracts.cgi. AccessedNovember 24 2009."},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.12.1955"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.126.209"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67426-5"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(96)00589-4"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-3565(24)35074-8","article-title":"KMD\u20103213, a uroselective and long\u2010acting \u03b11A\u2010adrenoceptor antagonist, tested in a novel rat model","volume":"291","author":"Akiyama K.","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-2042.2001.00277.x"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0022-3565(24)38308-9","article-title":"In vivo measurement by [3H]tamsulosin of \u03b1\u2010adrenoceptors in rat tissues in relation to the pharmacokinetics","volume":"289","author":"Yamada S.","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0022-3565(24)29676-2","article-title":"In vivo demonstration of \u03b11A\u2010adrenoceptor subtype selectivity of KMD\u20103213 in rat tissues","volume":"296","author":"Yamada S.","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_27_2","unstructured":"Watson Laboratories Inc.Data on file. Salt Lake City UT;2008."},{"key":"e_1_2_1_28_2","unstructured":"Watson Pharmaceuticals Inc.Rapaflo (silodosin) prescribing information. Morristown NJ;2008."},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.126.257"},{"key":"e_1_2_1_30_2","unstructured":"Watson Laboratories Inc.Kissei Pharmaceutical Co. study AL\u20102232\u2010G data on file. Morristown NJ;2004."},{"key":"e_1_2_1_31_2","unstructured":"HillLA VolinnW. HoelG.Exposure of the \u03b1\u2010blocker silodosin and its major metabolites in the plasma of healthy men [abstract].Presented at the American Society for Clinical Pharmacology and Therapeutics annual meeting National Harbor MD September 15 2009."},{"key":"e_1_2_1_32_2","unstructured":"Watson Laboratories Inc.Kissei Pharmaceutical Co. study KMD\u201011005 data on file. Morristown NJ;2004."},{"key":"e_1_2_1_33_2","unstructured":"HillLA VolinnW. HoelG.Effect of multiple doses of the cytochrome CYP03A4 inhibitor ketoconazole on the single\u2010dose pharmacokinetics of the highly selective \u03b11A\u2010adrenoceptor antagonist silodosin in healthy men [abstract].Presented at the American College of Clinical Pharmacy\u2010European Society for Clinical Pharmacy international congress on clinical pharmacy Orlando FL April 2428 2009."},{"key":"e_1_2_1_34_2","unstructured":"HillLA VolinnW. HoelG.Pharmacokinetics of silodosin and its primary metabolites in subjects with moderate liver dysfunction [abstract].Presented at the American Society for Clinical Pharmacology and Therapeutics annual meeting National Harbor MD September 15 2009."},{"key":"e_1_2_1_35_2","unstructured":"MarksLS GittelmanMC HillLA VolinnW. HoelG.Effect of renal impairment on plasma concentrations of silodosin and its main metabolites in patients with symptoms of benign prostatic hyperplasia [abstract].Presented at the American College of Clinical Pharmacy\u2010European Society for Clinical Pharmacy international congress on clinical pharmacy Orlando FL April 2428 2009."},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.06.072"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(09)61944-3"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00126-5"},{"key":"e_1_2_1_39_2","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/S0022-5347(01)62386-3","article-title":"A second phase III multicenter placebo\u2010controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia","volume":"160","author":"Narayan P.","year":"1998","journal-title":"J Urol"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.06448.x"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01880.x"},{"key":"e_1_2_1_42_2","first-page":"682","article-title":"Cardiovascular effects of the selective \u03b11A\u2010adrenoceptor antagonist silodosin (KMD\u20103213), a drug for the treatment of voiding dysfunction","volume":"56","author":"Tatemichi S.","year":"2006","journal-title":"Arzneim-Forsch Drug Res"},{"key":"e_1_2_1_43_2","unstructured":"HillLA VolinnW. HoelG.Maximum tolerated dose of silodosin a highly selective \u03b11A\u2010adrenoceptor antagonist for the treatment of symptoms associated with benign prostatic hyperplasia [abstract].Presented at the American College of Clinical Pharmacy\u2010European Society for Clinical Pharmacy international congress on clinical pharmacy Orlando FL April 2428 2009."},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.10.042"},{"key":"e_1_2_1_45_2","unstructured":"Sanofi\u2010aventis.Uroxatral (alfuzosin hydrochloride) prescribing information. Bridgewater NJ;2009."},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.128405"},{"key":"e_1_2_1_47_2","unstructured":"U.S. Food and Drug Administration.ICH E14: guidance for industry: E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs October 2005. Issued by the U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Center for Biologics Evaluation and Research. Approved by the International Conference on Harmonisation. Available fromhttp:www.fda. govcbergdlnsiche14qtc.pdf. AccessedJuly 23 2008."},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.265"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.30.12.1303","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.30.12.1303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:08:50Z","timestamp":1761048530000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.30.12.1303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1592\/phco.30.12.1303"],"URL":"https:\/\/doi.org\/10.1592\/phco.30.12.1303","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"2012-01-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}